Identification

Name
Ethchlorvynol
Accession Number
DB00189  (APRD00958)
Type
Small Molecule
Groups
Approved, Illicit, Withdrawn
Description

Ethchlorvynol is a sedative and hypnotic drug. It has been used to treat insomnia, but has been largely superseded and is only offered where an intolerance or allergy to other drugs exists. [Wikipedia]

Structure
Thumb
Synonyms
  • 1-chloro-3-ethyl-1-penten-4-yn-3-ol
  • 1-Chloro-3-ethyl-pent-1-en-4-yn-3-ol
  • 3-(beta-chlorovinyl)-1-pentyn-3-ol
  • 3-(β-chlorovinyl)-1-pentyn-3-ol
  • ethyl β-chlorovinyl ethynyl carbinol
  • β-chlorovinyl ethyl ethynyl carbinol
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Placidyl Cap 200mgCapsule200 mgOralAbbott1956-12-312008-06-10Canada
Placidyl Cap 500mgCapsule500 mgOralAbbott1952-12-312008-06-06Canada
Placidyl Cap 750mgCapsule750 mgOralAbbott1971-12-312008-06-06Canada
International/Other Brands
Arvynol (Pfizer) / Nostel (Dainippon) / Placidyl (Abbott) / Roeridorm (Pfizer-Roerig) / Serenesil (Abbott)
Categories
UNII
6EIM3851UZ
CAS number
113-18-8
Weight
Average: 144.599
Monoisotopic: 144.034192617
Chemical Formula
C7H9ClO
InChI Key
ZEHYJZXQEQOSON-AATRIKPKSA-N
InChI
InChI=1S/C7H9ClO/c1-3-7(9,4-2)5-6-8/h1,5-6,9H,4H2,2H3/b6-5+
IUPAC Name
1-chloro-3-ethylpent-1-en-4-yn-3-ol
SMILES
[H]C(Cl)=CC(O)(CC)C#C

Pharmacology

Indication

Used for short-term hypnotic therapy in the management of insomnia for periods of up to one week in duration; however, this medication generally has been replaced by other sedative-hypnotic agents.

Structured Indications
Not Available
Pharmacodynamics

Ethchlorvynol is a sedative drug and schedule IV (USA) controlled substance. It produces cerebral depression, however the exact mechanism of action is not known.

Mechanism of action

Although the exact mechanism of action is unknown, ethchlorvynol appears to depress the central nervous system in a manner similar to that of barbiturates. Barbiturates bind at a distinct binding sites associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.

TargetActionsOrganism
AGABA-A receptor (anion channel)
positive allosteric modulator
Human
Absorption

Rapidly absorbed from gastrointestinal tract.

Volume of distribution
Not Available
Protein binding

35-50%

Metabolism

About 90% of a dose is metabolized in the liver. Some ethchlorvynol may also be metabolized in the kidneys. Ethchlorvynol and metabolites undergo extensive enterohepatic recirculation.

Route of elimination
Not Available
Half life

Plasma half-life is approximately 10 to 20 hours, terminal half-life is 21-100 hours.

Clearance
Not Available
Toxicity

Symptoms of overdose include thrombocytopenia.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with 7-Nitroindazole.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Aceprometazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Ethchlorvynol.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ethchlorvynol.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Ethchlorvynol.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Amperozide.Experimental
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ethchlorvynol.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Ethchlorvynol.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Azaperone.Vet Approved
AzelastineEthchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Barbital.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Benzocaine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Benzyl alcohol.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ethchlorvynol.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Brotizolam.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Bupivacaine.Approved, Investigational
BuprenorphineEthchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Ethchlorvynol.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ethchlorvynol.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ethchlorvynol.Approved, Illicit, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Canertinib.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Ethchlorvynol.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Carisoprodol.Approved
CetirizineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ethchlorvynol.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Chloroprocaine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ethchlorvynol.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Chlorzoxazone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Cinchocaine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ethchlorvynol.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Ethchlorvynol.Approved
CocaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Ethchlorvynol.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ethchlorvynol.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dapoxetine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Ethchlorvynol.Approved
DesipramineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dexmedetomidine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Ethchlorvynol.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Diethyl ether.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ethchlorvynol.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ethchlorvynol.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ethchlorvynol.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Efavirenz.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Enflurane.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Entacapone.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Ethchlorvynol.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ethchlorvynol.Approved
EthanolEthchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ethyl chloride.Experimental
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ethchlorvynol.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ethchlorvynol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ethchlorvynol.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Ethchlorvynol.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fluspirilene.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Ethchlorvynol.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fospropofol.Approved, Illicit
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ethchlorvynol.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Ethchlorvynol.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Glutethimide.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Ethchlorvynol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Heroin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Hexobarbital.Approved
HydrocodoneEthchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ethchlorvynol.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Indiplon.Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Ethchlorvynol.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Ethchlorvynol.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ketobemidone.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ethchlorvynol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Lidocaine.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Lofentanil.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Ethchlorvynol.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Ethchlorvynol.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Ethchlorvynol.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Melperone.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ethchlorvynol.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Mesoridazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Ethchlorvynol.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Ethchlorvynol.Approved
MethotrimeprazineEthchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methylecgonine.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methylphenobarbital.Approved
MetyrosineEthchlorvynol may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Ethchlorvynol.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.Approved, Investigational
MirtazapineEthchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Ethchlorvynol.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ethchlorvynol.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Nefazodone.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Ethchlorvynol.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Ethchlorvynol.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Ethchlorvynol.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Opium.Approved, Illicit
OrphenadrineEthchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ethchlorvynol.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Oxethazaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ethchlorvynol.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ethchlorvynol.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ethchlorvynol.Approved
ParaldehydeEthchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ethchlorvynol.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Ethchlorvynol.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.Approved
PerazineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Ethchlorvynol.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Ethchlorvynol.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Phenazocine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Ethchlorvynol.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Phenoxyethanol.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Ethchlorvynol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pomalidomide.Approved
PramipexoleEthchlorvynol may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Ethchlorvynol.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Prilocaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ethchlorvynol.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Ethchlorvynol.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Ethchlorvynol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with PSD502.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Ethchlorvynol.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ethchlorvynol.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ramelteon.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ethchlorvynol.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Ethchlorvynol.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Ethchlorvynol.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Romifidine.Vet Approved
RopiniroleEthchlorvynol may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ropivacaine.Approved
RotigotineEthchlorvynol may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Ethchlorvynol.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ethchlorvynol.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ethchlorvynol.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.Approved
StiripentolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ethchlorvynol.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Sulpiride.Approved
SultoprideThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Sultopride.Experimental
SuvorexantEthchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tasimelteon.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Ethchlorvynol.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tetrodotoxin.Investigational
ThalidomideEthchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Ethchlorvynol.Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Ethchlorvynol.Approved
TiagabineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tilidine.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Ethchlorvynol.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Ethchlorvynol.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Trichloroethylene.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ethchlorvynol.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Triflupromazine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Triprolidine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Valproic Acid.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Ethchlorvynol.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Ethchlorvynol.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Zolazepam.Vet Approved
ZolpidemEthchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Ethchlorvynol.Approved
ZotepineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ethchlorvynol.Approved, Investigational
Food Interactions
  • Avoid alcohol
  • Take with food to reduce irritation.

References

Synthesis Reference

Bayley, A. and McLamore, W.M.; U.S. Patent 2,746,900; May 22,1956; assigned to Chas. Pfizer & Co., Inc.

General References
Not Available
External Links
KEGG Drug
D00704
KEGG Compound
C07833
PubChem Compound
5281077
PubChem Substance
46505006
ChemSpider
4444534
ChEBI
4882
ChEMBL
CHEMBL591
Therapeutic Targets Database
DAP000163
PharmGKB
PA164746383
Drugs.com
Drugs.com Drug Page
Wikipedia
Ethchlorvynol
ATC Codes
N05CM08 — Ethchlorvynol

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
  • Banner pharmacaps inc
  • Abbott laboratories pharmaceutical products div
Packagers
Not Available
Dosage forms
FormRouteStrength
CapsuleOral200 mg
CapsuleOral500 mg
CapsuleOral750 mg
Prices
Not Available
Patents
Not Available

Properties

State
Liquid
Experimental Properties
PropertyValueSource
boiling point (°C)28.5-30Bayley, A. and McLamore, W.M.; U.S. Patent 2,746,900; May 22,1956; assigned to Chas. Pfizer & Co., Inc.
logP1.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.143 mg/mLALOGPS
logP1.45ALOGPS
logP1.62ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)12.88ChemAxon
pKa (Strongest Basic)-3.7ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area20.23 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity38.64 m3·mol-1ChemAxon
Polarizability14.77 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9965
Blood Brain Barrier+0.9685
Caco-2 permeable+0.646
P-glycoprotein substrateNon-substrate0.743
P-glycoprotein inhibitor INon-inhibitor0.9023
P-glycoprotein inhibitor IINon-inhibitor0.9672
Renal organic cation transporterNon-inhibitor0.9589
CYP450 2C9 substrateNon-substrate0.7267
CYP450 2D6 substrateNon-substrate0.9
CYP450 3A4 substrateNon-substrate0.6176
CYP450 1A2 substrateNon-inhibitor0.5224
CYP450 2C9 inhibitorNon-inhibitor0.6241
CYP450 2D6 inhibitorNon-inhibitor0.9316
CYP450 2C19 inhibitorInhibitor0.5539
CYP450 3A4 inhibitorNon-inhibitor0.7814
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7382
Ames testAMES toxic0.867
CarcinogenicityCarcinogens 0.8102
BiodegradationNot ready biodegradable0.9614
Rat acute toxicity2.7881 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9406
hERG inhibition (predictor II)Non-inhibitor0.9289
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as ynones. These are organic compounds containing the ynone functional group, an alpha,beta unsaturated ketone group with the general structure RC#C-C(=O)R' (R' not H).
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbonyl compounds
Direct Parent
Ynones
Alternative Parents
Tertiary alcohols / Vinyl chlorides / Chloroalkenes / Acetylides / Organochlorides / Hydrocarbon derivatives
Substituents
Ynone / Tertiary alcohol / Acetylide / Chloroalkene / Haloalkene / Vinyl halide / Vinyl chloride / Hydrocarbon derivative / Organochloride / Organohalogen compound
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
terminal acetylenic compound, tertiary alcohol, organochlorine compound, enyne (CHEBI:4882)

Targets

Kind
Protein group
Organism
Human
Pharmacological action
Yes
Actions
Positive allosteric modulator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...

Components:
References
  1. Smeyatsky N, Baldwin D, Botros W, Gura R, Kurian T, Lambert MT, Patel AG, Steinert J, Priest RG: The treatment of sleep disorders. S Afr Med J. 1992 May 2;Suppl:1-8. [PubMed:1585214]
  2. ChEMBL Compound Report Card [Link]

Drug created on June 13, 2005 07:24 / Updated on October 02, 2017 04:32